SEC Filing Analysis: THE COOPER COMPANIES, INC. (COO)

Executive Summary

• Trading Significance: High
• Key Takeaway: CooperCompanies delivered a strong Q1 with 20% Non-GAAP EPS growth, raised full-year guidance, and executed a significant $92.5M share buyback.
• Market Impact: Positive sentiment expected due to the earnings beat, guidance raise, and active capital return.

Company Information

Field	Value
Company	THE COOPER COMPANIES, INC.
Ticker Symbol	COO
CIK	0000711404
Industry	Medical Devices

Transaction Details (Share Repurchase)

Field	Value
Form Type	8-K
Transaction Period	Q1 Ended Jan 31, 2026
Transaction Type	Share Repurchase
Security Type	Common Stock
Shares Transacted	~1,100,000
Average Price	$82.04
Total Value	$92,500,000
Remaining Authorization	$873.9 million

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$92,500,000
% of Market Cap	0.56%
Shares Transacted	1,100,000
% of Shares Outstanding	0.56%
Materiality Assessment	Significant

Impact Evaluation

• Market Cap Context: With a market cap of $16.40 billion, a $92.5M quarterly buyback represents a solid annualized capital return yield (>2%).
• Capital Allocation: The company generated $158.7M in free cash flow and returned 58% of it to shareholders via buybacks this quarter.
• Transaction Significance: The repurchase of 0.56% of outstanding shares in a single quarter is significant, indicating management believes the stock is undervalued or is committed to offsetting dilution.

Market Impact Analysis

Stock Impact Prediction

• Direction: Positive
• Reasoning: The combination of a "beat and raise" quarter (Revenue +6%, EPS +20%) alongside a substantial buyback program provides strong fundamental support for the stock price.

Volume & Sentiment

• Expected Volume Impact: High volume expected as the market digests the earnings beat and guidance update.
• Sentiment Indicator: Bullish. The raised guidance suggests confidence in the remainder of fiscal 2026.

Investment Insights

Positive Market Indicators

• Guidance Raise: Fiscal 2026 revenue guidance raised to $4.306 - $4.346 billion.
• Margin Expansion: Non-GAAP operating margin expanded 180 basis points to 27%.
• Strong Cash Flow: Free cash flow of $158.7M supports continued debt reduction and buybacks.

Key Takeaways

1. Operational Strength: CooperVision and CooperSurgical both showed organic growth, with CooperVision growing 8% reported.
2. Shareholder Returns: The company is actively using its cash flow to reduce share count, repurchasing ~1.1 million shares.
3. Future Outlook: Management remains on track for long-term goals, projecting >$2.2 billion in free cash flow from 2026-2028.

Additional Context

Transaction Notes

• Timing: Repurchases occurred during Q1 fiscal 2026 (Nov 2025 - Jan 2026).
• Market Environment: The medical device sector is navigating tariff and FX headwinds, yet COO delivered 3% constant currency growth.